Gena Wang: Okay. Have you already received the payment or you were received after the transaction close regarding the show?
Michelle Robertson: We have already – yes we have received the payment Gena.
Gilmore O’Neill: Yes. Actually, fair enough. I actually forgot to answer your part of your question, Gena, which is that we have closed the deal, we have received the payment. Yes.
Michelle Robertson: The payment was received in 2023.
Gena Wang: I see. So the cash reported already incorporate that.
Michelle Robertson: The cash reported at the end of the year did not yet include that.
Gena Wang: Okay. The guidance that will -.
Michelle Robertson: That will be in our reforecast of our cash runway.
Gena Wang: Okay. Sounds good. And the second question very quick, just I know you are committed to present a data 301 RUBY trial mid-year. What about the end of 2023, especially like ASH. Will you also provide some update there and thoughts on the timing and also number of patients?
Gilmore O’Neill: Yes. Thanks, Gena, I’m going to ask Baisong to answer that question, but confirm that we are planning to present updates both the middle of this year and at the end of this year. Baisong.
Baisong Mei: Yes, thanks Gena for the question. Yes, we will plan to have two data released for RUBY study. One is the middle of the year, and one is the end of the year. In terms of specific forum, we will share when we have more information. And we have not shared the number patient this point, but I just mentioned earlier we really have a strong momentum for the RUBY study as well as EDITHAL study. And we expect to have multiple patient data for the data release.
Gena Wang: Okay. And then lastly, very quick, in-vivo programs beyond HSC, what would be your top organ to explore?
Gilmore O’Neill: Thanks very much, Gena. We actually have taken the approach that we will use a sort of a balance of multiple factors in selecting our targets, our therapeutic targets, and for ergo the target tissues. And that will be a balance of the state of the technology, the probability of clinical regulatory and commercial success. And we look forward to sharing more specifics on that in the future.
Gena Wang: Thank you.
Gilmore O’Neill: Thanks very much
Operator: Our next question is from Rich Law with Credit Suisse. Please proceed.
Richard Law: Good morning and thanks for taking my question. So as you focus on in-vivo development, is there any renew interest in using CRISPR/Cas9 in addition to Cas12 for internal product development? Since the Cas9 life technology is arguably more mature from the development progress by other companies. And then I have a follow-up question to that.
Gilmore O’Neill: Thanks very much, Rich. I have to say that our pipeline currently is focused on AsCas12a, we believe that the AsCas12a enzyme has some significant advantages. We actually also believe that now we have used it in the clinic. And actually, as Baisong has said, we have already edited multiple patients in addition to those already dosed. So we actually are building a clinical experience with AsCas12a. And from the point of its advantages we believe that and actually have data supporting that position that it has a higher efficiency and essentially higher fidelity with much less off-target editing. So a substantial advantages for moving forward.
